Evidence map›Paper›PMID 32368168›Full record

ArticleLung Cancer (Auckland, N.Z.)2020

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the

Alexa B Schrock, Russell Madison, Mark Rosenzweig, Justin M Allen, Rachel L Erlich, Siao-Yi Wang, Tarek Chidiac, Vodur Suresh Reddy, Jonathan W Riess, Ahmet Ersin Yassa and 6 more

Open access · goldAbstract read
In one paragraph

Article in Lung Cancer (Auckland, N.Z.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Lung adenocarcinoma withTranslational lung cancer research · 2025
    Article
  2. Article
  3. JTO clinical and research reports · 2023
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Alexa B SchrockFoundation Medicine, Department of Clinical Development, Cambridge, MA, USA.
Russell MadisonFoundation Medicine, Department of Clinical Development, Cambridge, MA, USA.ORCID 0000-0002-7838-2526
Mark RosenzweigFoundation Medicine, Department of Translational Oncology and Clinical Reporting, Cambridge, MA, USA.
Justin M AllenFoundation Medicine, Department of Translational Oncology and Clinical Reporting, Cambridge, MA, USA.
Rachel L ErlichFoundation Medicine, Department of Translational Oncology and Clinical Reporting, Cambridge, MA, USA.
Siao-Yi WangLoyola University Medical Cancer, Department of Hematology and Oncology, Maywood, IL, USA.
Tarek ChidiacZangmeister Cancer Center, Department of Hematology and Oncology, Columbus, OH, USA.
Vodur Suresh ReddyCancer Care Specialists, Department of Hematology and Oncology, Reno, NV, USA.
Jonathan W RiessUC Davis Comprehensive Cancer Center, Department of Hematology and Oncology Sacramento, CA, USA.
Ahmet Ersin YassaUC Davis Comprehensive Cancer Center, Department of Hematology and Oncology Sacramento, CA, USA.ORCID 0000-0002-8928-3435
Abdur ShakirSarah Bush Lincoln Health System, Department of Medical Oncology, Mattoon, IL, USA.ORCID 0000-0003-1007-9659
Vincent A MillerFoundation Medicine, Department of Clinical Development, Cambridge, MA, USA.
Brian M AlexanderFoundation Medicine, Department of Clinical Development, Cambridge, MA, USA.ORCID 0000-0003-3903-9175
Jeffrey VenstromFoundation Medicine, Department of Clinical Development, Cambridge, MA, USA.
Kimberly McGregorFoundation Medicine, Department of Clinical Development, Cambridge, MA, USA.ORCID 0000-0002-9185-5869
Siraj M AliFoundation Medicine, Department of Clinical Development, Cambridge, MA, USA.
Foundation Medicine (United States)UC Davis Comprehensive Cancer CenterMark H. Zangmeister Cancer Center · USSarah Bush Lincoln Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsComprehensive genomic profiling (CGP) of DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue or blood-based circulating tumor DNA was performed for 39,159 NSCLC patients during routine clinical care. For a subset of cases, RNA sequencing was performed, and prior ALK test results and clinical treatment information were collected from treating physicians.

resultsWe queried the Foundation Medicine NSCLC database and identified ALK internal inversions, as well as internal deletions, as the sole

conclusionRare internal inversions of

Indexed as

ALK rearrangementdeletiongenomic profilinginversiontargeted therapy

Identifiers

PMID32368168
PMCPMC7184117
OpenAlexW3016642011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.